by Stacey Johnson | Jul 9, 2026
Celebrity health stories often dominate headlines, but their impact extends beyond entertainment news. High-profile diagnoses can raise awareness of rare diseases, increase participation in clinical trials, influence health policy, and accelerate investment in...
by Lyla El-Fayomi | Jun 24, 2026
Patients diagnosed with degenerative eye disorders, such as retinitis pigmentosa (RP) or choroideremia, face a gradual loss of light-sensing cells that eventually leads to blindness. Historically, most treatments could only aim to slow disease progression; however,...
by Michael May | Jun 9, 2026
Fifteen years ago, regenerative medicine in Canada stood at an inflection point. The science was world-class, the academic talent was undeniable, and the promise of cell and gene therapies was beginning to capture global attention. Yet there was a critical problem:...
by Krystal Jacques | Apr 28, 2026
Spontaneous neuronal regrowth and repair are not observed in adult spinal cords, making paralysis from spinal cord injury devastating and often permanent. In a new study, Professor Samuel Stupp’s research team at Northwestern University created human spinal cord...
by Cal Strode | Jan 28, 2026
This year marks the fourth consecutive time I’ve covered the Alliance for Regenerative Medicine’s (ARM) State of the Industry briefing for Signals, and I’ve enjoyed tracking how the cell and gene therapy sector has evolved in real time. In 2023 and 2024, the briefings...
by Cal Strode | Dec 1, 2025
To mark World AIDS Day, I revisited the rapidly shifting HIV cure research landscape, checking in on International AIDS Society (IAS) 2025 to see how things have evolved since 2021, when I last covered progress for Signals. Curative approaches are starting to move on...
Comments